M1FG
ITCI

Mach-1 Financial Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Mach-1 Financial Group’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-7,180
Closed -$514K – 235
2023
Q4 		$514K Buy
+7,180
New +$413K 0.2% 102
2023
Q1 		– Sell
-11,031
Closed -$584K – 352
2022
Q4 		$584K Buy
+11,031
New +$553K 0.19% 96

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Mach-1 Financial Group's ITCI Position: Q1 2024 in Review

Mach-1 Financial Group sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2024, closing a stake of 7,180 shares — an estimated $514K sold.

Mach-1 Financial Group first reported a position in ITCI in Q4 2022 and held it in 2 quarters. The position peaked at $584K in Q4 2022. 346 funds tracked by Wall St. Rank hold ITCI as of Q1 2024.

  • Mach-1 Financial Group reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2024 after selling out during the quarter.
  • Mach-1 Financial Group sold 7,180 Intra-Cellular Therapies Inc. shares in Q1 2024, an estimated $514K.
  • Mach-1 Financial Group first reported a position in Intra-Cellular Therapies Inc. in Q4 2022 and held it in 2 quarters.
  • Mach-1 Financial Group's Intra-Cellular Therapies Inc. position peaked at $584K in Q4 2022.
  • 346 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2024.

Based on Mach-1 Financial Group's 13F filing for Q1 2024, filed 10 May 2024.